Anti-human sFlt-1 Antibody, Igundane Monoclonal
Imininingwane yomkhiqizo
Ulwazi oluvamile
I-Preeclampsia iyinkinga ebucayi yokukhulelwa enezinhlelo eziningi, eyenzeka ku-3 - 5 % wokukhulelwa, futhi ingenye yezimbangela eziphambili zokugula nokufa komama kanye nokufa kwabantu abakhulelwe emhlabeni wonke.
I-Preeclampsia ichazwa njengokuqalwa okusha komfutho wegazi ophakeme kanye ne-proteinuria ngemva kwamasonto angu-20 okukhulelwa.Isethulo somtholampilo se-preeclampsia kanye nenkambo yomtholampilo elandelayo yalesi sifo ingahluka kakhulu, okwenza kube nzima ukubikezela, ukuxilongwa nokuhlolwa kokuqhubeka kwesifo.
Izici ze-angiogenic (sFlt-1 kanye ne-PlGF) zifakazelwa ukuthi zidlala indima ebalulekile ku-pathogenesis ye-preeclampsia futhi ukugxila kwazo ku-serum kamama kuyashintshwa ngisho nangaphambi kokuqala kwesifo okuwenza abe yithuluzi lokubikezela nokusiza ekuxilongeni i-preeclampsia.
Izakhiwo
| Bhanqa Isincomo | I-CLIA (Ukutholwa-Thatha): 1E4-6 ~ 2A6-4 2A6-4 ~ 1E4-6 |
| Ubumsulwa | >95% njengoba kunqunywa i-SDS-PAGE. |
| Ukwakhiwa Kwesigcinalwazi | I-PBS, pH7.4. |
| Isitoreji | Igcine ngaphansi kwezimo eziyinyumba ku -20℃ ukuya ku -80 ℃ uma yamukelwa. Ncoma ukuthi i-aliquot iphrotheni ibe ngamanani amancane ukuze uthole isitoreji esiphezulu. |
Ukuqhathanisa Ngokuncintisana
Oda Ulwazi
| Igama Lomkhiqizo | Ikati.Cha | I-Clone ID |
| sFlt-1 | I-AB0029-1 | 1E4-6 |
| I-AB0029-2 | 2A6-4 | |
| AB0029-3 | 2H1-5 | |
| AB0029-4 | 4D9-10 |
Qaphela: I-Bioantibody ingakwazi ukwenza amanani ngendlela oyifisayo ngokwesidingo sakho.
Izingcaphuno
1.Stepan H , Geide A , Faber R .I-soluble fms-like tyrosine kinase 1.[J].N Engl J Med, 2004, 351(21):2241-2242.
2.Kleinrouweler CE , Wiegerinck M , Ris-Stalpers C , et al.Ukunemba kokujikeleza kwe-placenta factor, i-vascular endothelial growth factor, i-soluble fms-like tyrosine kinase 1 kanye ne-endoglin encibilikayo ekubikezelweni kwe-pre-eclampsia: ukubuyekezwa okuhlelekile nokuhlaziywa kwe-meta.[J].I-Bjog An International Journal of Obstetrics & Gynaecology, 2012, 119(7):778-787.
